Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
Active, not recruiting · Phase 1 · NCT04721015
Conditions: Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)
At a glance
- Research payments reported, 2025
- $12,489
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 81
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-637 (drug), Docetaxel (drug), Osimertinib (drug)
- Dates
- Started 2021-02-23; completion 2026-02
- Results posted
- Not yet
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to evaluate the safety and efficacy (how well the study drug works against the disease) of ABBV-637 alone or in combination with docetaxel/osimertinib in participants with solid tumors (NSCLC). Adverse events and change in disease activity will be assessed. ABBV-637 is an investigational drug being developed for the treatment of solid tumors. Study consists of 3 parts - monotherapy dose escalation (Part 1), combination dose escalation and expansion (…
From ClinicalTrials.gov, last updated 2025-07-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $12,489 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Washington University in St Louis $12,489
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.